Earlier meta-analyses did report a small on-medication motor benefit, roughly one to three points, but that effect is heterogeneous and fragile: in at least one pooled analysis, it lost statistical significance once the lixisenatide trial was removed [8]
Pre-blend 12.5/2.5 mg + 2.5 mL BAC 5 mg/mL reta + 1 mg/mL cag
Third-party testing may make the product more expensive, but its a clear sign that youre consuming a safe, transparent supplement
Findings GLP-1 RAs exhibit potential beneficial effects on depressive symptoms, cognitive function, and reduced risk of suicidal ideation in animal and human models through antioxidative, anti-inflammatory mechanisms, and modulation of neurotransmitter pathways
In February 2024, Regeneron announced plans to launch a phase 2 trial in mid-2024 that will test combining semaglutide for obesity with either trevogrumab or trevogrumab and garetosmab